Survival Analysis

How it works

Comparisons

Evidence quality

Other

Highlighted claims

• The primary outcome is overall survival at 1 and 5 years after diagnosis. — Stereotactic ablative radiotherapy versus video-assisted lobectomy for operable stage I non-small-cell lung cancer: study protocol for an emulated target trial
• Secondary outcomes are cancer-specific survival and recurrence-free survival. — Stereotactic ablative radiotherapy versus video-assisted lobectomy for operable stage I non-small-cell lung cancer: study protocol for an emulated target trial
• Overall survival is calculated from diagnosis until death from any cause or the end of follow-up. — Stereotactic ablative radiotherapy versus video-assisted lobectomy for operable stage I non-small-cell lung cancer: study protocol for an emulated target trial
• Treatment effects will be estimated using survival probability differences and restricted mean survival time differences over 1-year and 5-year windows. — Stereotactic ablative radiotherapy versus video-assisted lobectomy for operable stage I non-small-cell lung cancer: study protocol for an emulated target trial
• Artificial censoring is handled with inverse probability of censoring weights because censoring is informative. — Stereotactic ablative radiotherapy versus video-assisted lobectomy for operable stage I non-small-cell lung cancer: study protocol for an emulated target trial
• The protocol acknowledges that cloning and inverse probability weighting reduce but do not eliminate confounding. — Stereotactic ablative radiotherapy versus video-assisted lobectomy for operable stage I non-small-cell lung cancer: study protocol for an emulated target trial